Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.

This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.

Open Letter to MAPS Canada, MAPS, and MAPS PBC on Data Privacy and Doxxing. We believe that an organization responsible for private data, in such close proximity to criminalized subcultures, must take matters of privacy and security seriously.

Last Week Tonight joined a long and growing list of media outlets that have added fuel to the hype of psychedelic medicalization. By omitting the potential risks and actual harms associated with psychedelic-assisted therapy, this messaging increases the risk to the public by presenting unrealistic expectations about experimental treatments.

Psymposia editors discuss Dr. Martin Ball’s “session info” document that the retired 5-MeO-DMT practitioner sent to Psymposia. Dr. Ball has referenced the document in defense of his practices and cites it as evidence that his clients consented to him touching their genitals or vomiting on them while under the influence of 5-MeO-DMT.

As I became activated to defend something bigger than my own immediate welfare, a shift took place—a shift toward seeing reality as a singular entity as opposed to a bunch of disjointed parts.

So much of the conversation surrounding sex, like that surrounding drugs, is fear-based and chock full of negativity.

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”